In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Cephalon acquires Anesta in $444mm stock swap

Executive Summary

Enhancing its clinical development pipeline, Cephalon will acquire all outstanding shares of Anesta (oral transmucosal drug delivery) for $31.45 each-a (pr)32% premium--in an all-stock merger valued at $444mm or about 68 times Anesta's sales. Should Anesta withdraw from the deal, it is required to pay Cephalon a $15mm termination fee.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Intra-Biotech Deal
    • Payment Includes Stock

Related Companies